Study of ADCs Combined With Adebrelimab in HER2-negative Advanced Breast Cancer
ConditionAdvanced Breast Cancer
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18-75
SponsorBeijing GoBroad Hospital
About this trial
Our study is aimed to evaluate the efficacy and safety of novel ADCs named SHR-A1811, SHR-A1921 and SHR-A2102 combined with adebrelimab in HER2-negative advanced breast cancer.
Eligibility criteria
Qualifiers
18 years to 75 years old (including boundary values);
ECOG PS Score: 0~1;
Histologically or cytologically confirmed HER2-negative advanced breast cancer;
Disease progression after prior ≥1 line of systemic therapy; if HR-positive, prior CDK4/6 inhibitor is necessary;
Disqualifiers
Has known active brain metastasis which needs local therapy immediately;
Prior use of ADCs with the same target as study drugs;
Existence of third space fluid that is not well controlled by effective methods, e.g. drainage;
Has received antitumor surgery, radiotherapy, chemotherapy, targeted therapy or immunological therapy within 4 weeks before first dose of study therapy; has received antitumor endocrine therapy within one week before first dose of study therapy;
Trial design
Treatments tested in this trial
- SHR-A1811
- SHR-A1921
- Adebrelimab
- SHR-A2102
Treatment groups
113 Participants
are divided into 3 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov